Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3734678 | 0.94 | PTPN1 (0.88) | PTPN1 | |
| SCHEMBL13040908 | 0.91 | PTPN1 (1.00) | PTPN1 | |
| SCHEMBL3732057 | 0.90 | PTPN1 (1.00) | PTPN1 | |
| SCHEMBL4381209 | 0.90 | PTPN1 (0.82) | PTPN1 | |
| SCHEMBL4374694 | 0.90 | PTPN1 (0.85) | PTPN1 | |
| SCHEMBL13040924 | 0.87 | PTPN1 (0.83) | PTPN1 | |
| SCHEMBL4374325 | 0.87 | PTPN1 (0.81) | PTPN1 | |
| SCHEMBL4378710 | 0.87 | PTPN1 (0.81) | PTPN1 | |
| SCHEMBL4376458 | 0.87 | PTPN1 (0.81) | PTPN1 | |
| Trifluoroacetic Acid SCHEMBL3742933 | 0.85 | PTPN1 (0.75) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910359-B1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | claimed |
| EP-1910359-A1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | claimed |
| WO-2007009911-A1 | PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | claimed |
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2010-11-04 | — | — | US | disclosed |
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2010-11-04 | — | — | US | disclosed |
| EP-1910359-B1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-20090062276-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2009-03-05 | — | — | US | disclosed |
| US-20090062276-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2009-03-05 | — | — | US | disclosed |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-01-25 | — | — | US | disclosed |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062276-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PTPRF, PTPN1, PTPRCAP | PTPN1 2/4885 |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | PTPRF, PTPN1, PTPRCAP | PTPN1 2/4885 |
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PTPRF, PTPN1, PTPRCAP | PTPN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.